Clinical trial

Safety Study of MGA271 in Refractory Cancer

NCT01391143

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-07-01

PhasePHASE1

Study timeline

Study start (unknown)2011-07-01Date precision: month

Registry last updated2022-02-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Melanomaunresolved

Renal Cell Carcinomaunresolved

Triple-negative Breast Cancerunresolved

Head and Neck Cancerunresolved

Bladder Cancerunresolved

Non-small Cell Lung Cancerunresolved

Interventions

MGA271BIOLOGICAL

Sponsors & collaborators

MacroGenicslead sponsor

Mapped research locations

BostonMassachusetts, United States3 ChicagoIllinois, United States1 Los AngelesCalifornia, United States1 PhiladelphiaPennsylvania, United States1 BaltimoreMaryland, United States1 NashvilleTennessee, United States1 TampaFlorida, United States1 New HavenConnecticut, United States1 LouisvilleKentucky, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01391143 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.